Metropolis Healthcare Limited has informed the Exchange about Transcript

Metropolis Healthcare reported strong Q4 FY26 results with group revenue of INR 425 crores (23% YoY) and EBITDA margin of 25.4%. For FY26, revenue stood at INR 1,646 crores (23.6% YoY) with EBITDA margin of 24.4%. The company delivered organic revenue growth of 13.7%, exceeding its stated guidance of 12-13%, with organic margins expanding by 140 basis points to 25.9%. Management guided for 14-15% revenue CAGR over the next 3 years, with patient volume growth of 8-9% and realization improvement of ~5%. Key growth drivers include TruHealth (21% YoY, 19% of revenue), Specialty (16% YoY, 37% of revenue), and genomics expansion. The Core Diagnostics acquisition has been successfully turned around to high-single-digit EBITDA within 4 quarters as committed. Management targets EBITDA margin of 27-28% over the next 3 years, expecting 125-150 bps improvement in FY27.